Halozyme Therapeutics Inc experienced a notable increase in its stock price, reflecting strong investor confidence.
Shares of Halozyme Therapeutics Inc (NASDAQ:HALO) went up yesterday by 6.57%, closing at CA$116.82. This surge can be attributed to positive sentiment surrounding the company's growth prospects and strong earnings potential.
Advertisement
Halozyme Therapeutics Inc
HALO.US
HALO.US
Halozyme Therapeutics Inc
WealthAwesomeMarket cap
$13.79B
P/E
35.5x
52W high
$122.33
52W low
$61.23
1W change
+10.62%
Beta
0.88
Analyst Price Targets
Based on 9 analysts covering HALO · as of Oct 16, 2026
Wall Street analysts forecast HALO stock price to fall 10.5% over the next 12 months.
Consensus
Buy4.33 / 5.00
Avg. Target
C$108.78
-10.5% Upside
Previously C$104.89 on Oct 14, 2026
Current Price
C$121.51
Last close
Analyst Breakdown (9 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HALO's historical volatility
30-Day Vol
32.9%
Annualized
90-Day Vol
42.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$145.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$128.96 | C$115.11 – C$144.49 |
| 60 trading days | C$136.87 | C$116.55 – C$160.74 |
| 90 trading days | C$145.27 | C$119.31 – C$176.87 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the growth potential of Halozyme Therapeutics, especially given its impressive earnings growth forecast and favorable market conditions.
6.57% Surge in Stock Price
Halozyme's stock price increase reflects strong investor confidence and positive growth projections.
Bull case
Halozyme is expected to see its earnings per share (EPS) grow by 112.1% this year. This positions the company to outperform its peers, making it an attractive choice for investors focused on growth.
Bear case
Even with a positive outlook, investors should be cautious about market volatility and the risks that come with the biotech sector, which can affect stock performance.
Strong Earnings Growth Forecast
Advertisement
Halozyme Therapeutics has been highlighted for its impressive earnings growth potential, with analysts projecting a 112.1% increase in EPS this year. This far exceeds the industry average of 14.7%, indicating robust business performance.
Positive Market Sentiment
The recent surge in Halozyme's stock can also be attributed to favorable market conditions and investor sentiment. As the company continues to innovate and expand its product offerings, confidence in its future performance remains high.
Comparison with Industry Peers
Halozyme's asset utilization ratio of 0.67, compared to the industry average of 0.33, underscores its efficiency in generating sales. This efficiency, combined with strong projected sales growth of 35.1%, positions Halozyme favorably against its competitors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
